133 related articles for article (PubMed ID: 17636541)
1. Antibody responses to survivin and their clinical significance in patients with head and neck cancer.
Eto M; Kodama S; Uemura N; Suzuki M
Head Neck; 2007 Dec; 29(12):1128-35. PubMed ID: 17636541
[TBL] [Abstract][Full Text] [Related]
2. Detection of autoantibodies to survivin and livin in sera from patients with breast cancer.
Yagihashi A; Ohmura T; Asanuma K; Kobayashi D; Tsuji N; Torigoe T; Sato N; Hirata K; Watanabe N
Clin Chim Acta; 2005 Dec; 362(1-2):125-30. PubMed ID: 16026775
[TBL] [Abstract][Full Text] [Related]
3. Detection of autoantibodies to livin and survivin in Sera from lung cancer patients.
Yagihashi A; Asanuma K; Kobayashi D; Tsuji N; Shijubo Y; Abe S; Hirohashi Y; Torigoe T; Sato N; Watanabe N
Lung Cancer; 2005 May; 48(2):217-21. PubMed ID: 15829321
[TBL] [Abstract][Full Text] [Related]
4. A new prognostic indicator for head and neck cancer--p53 serum antibodies?
Gottschlich S; Folz BJ; Goeroegh T; Lippert BM; Maass JD; Werner JA
Anticancer Res; 1999; 19(4A):2703-5. PubMed ID: 10470224
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection.
Megliorino R; Shi FD; Peng XX; Wang X; Chan EK; Tan EM; Zhang JY
Cancer Detect Prev; 2005; 29(3):241-8. PubMed ID: 15896923
[TBL] [Abstract][Full Text] [Related]
6. Combined evaluation of expression of telomerase, survivin, and anti-apoptotic Bcl-2 family members in relation to loss of differentiation and apoptosis in human head and neck cancers.
Sharma H; Sen S; Mathur M; Bahadur S; Singh N
Head Neck; 2004 Aug; 26(8):733-40. PubMed ID: 15287041
[TBL] [Abstract][Full Text] [Related]
7. Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: implications for specific immunotherapy.
Kitamura H; Torigoe T; Honma I; Asanuma H; Nakazawa E; Shimozawa K; Hirohashi Y; Sato E; Sato N; Tsukamoto T
Urology; 2006 May; 67(5):955-9. PubMed ID: 16635519
[TBL] [Abstract][Full Text] [Related]
8. p53 autoantibodies as tumor marker in head and neck squamous cell cancer.
Gottschlich S; Hoffmann M; Maass JD; Görörgh T; Buhmann V; Hoffmann-Fazel A; Rudert H; Maune S
Anticancer Res; 2003; 23(2A):913-5. PubMed ID: 12820322
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
[TBL] [Abstract][Full Text] [Related]
10. Autoantibodies to survivin in patients with chronic hepatitis and hepatocellular carcinoma.
Yagihashi A; Asanuma K; Kobayashi D; Tsuji N; Torigoe T; Sato N; Watanabe N
Autoimmunity; 2005 Sep; 38(6):445-8. PubMed ID: 16278150
[TBL] [Abstract][Full Text] [Related]
11. The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck.
Inal E; Laçin M; Asal K; Ceylan A; Köybaşioğlu A; Ileri F; Uslu SS
Kulak Burun Bogaz Ihtis Derg; 2004; 12(1-2):23-30. PubMed ID: 16010093
[TBL] [Abstract][Full Text] [Related]
12. Head and neck cancer and p53-immunogenicity.
Maass JD; Gottschlich S; Goeroegh T; Lippert BM; Werner JA
Anticancer Res; 1997; 17(4B):2873-4. PubMed ID: 9329551
[TBL] [Abstract][Full Text] [Related]
13. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients.
Rohayem J; Diestelkoetter P; Weigle B; Oehmichen A; Schmitz M; Mehlhorn J; Conrad K; Rieber EP
Cancer Res; 2000 Apr; 60(7):1815-7. PubMed ID: 10766164
[TBL] [Abstract][Full Text] [Related]
14. SCC-RIA in the diagnosis of squamous cell carcinoma of the head and neck.
Eibling DE; Johnson JT; Wagner RL; Su S
Laryngoscope; 1989 Feb; 99(2):117-24. PubMed ID: 2913421
[TBL] [Abstract][Full Text] [Related]
15. Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck.
Lavieille JP; Lubin R; Soussi T; Reyt E; Brambilla C; Riva C
Anticancer Res; 1996; 16(4C):2385-8. PubMed ID: 8816839
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma.
Riedel F; Zaiss I; Herzog D; Götte K; Naim R; Hörmann K
Anticancer Res; 2005; 25(4):2761-5. PubMed ID: 16080523
[TBL] [Abstract][Full Text] [Related]
17. CYFRA 8/18 in head and neck cancer.
Maass JD; Niemann AM; Lippert BM; Gottschlich S; Folz BJ; Werner JA
Anticancer Res; 1999; 19(4A):2699-701. PubMed ID: 10470223
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of elevated osteopontin levels in head and neck cancer patients.
Eto M; Kodama S; Nomi N; Uemura N; Suzuki M
Auris Nasus Larynx; 2007 Sep; 34(3):343-6. PubMed ID: 17254728
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma.
Van Hal NL; Van Dongen GA; Ten Brink CB; Heider KH; Rech-Weichselbraun I; Snow GB; Brakenhoff RH
Clin Cancer Res; 1999 Nov; 5(11):3534-41. PubMed ID: 10589769
[TBL] [Abstract][Full Text] [Related]
20. Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies.
Moch C; Moysan A; Lubin R; de la Salmonière P; Soufir N; Galisson F; Vilmer C; Venutolo E; Le Pelletier F; Janin A; Basset-Séguin N
Br J Cancer; 2001 Dec; 85(12):1883-6. PubMed ID: 11747330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
